

INDEX

Note: Page numbers of article titles are in **boldface** type.

- Abscess, crypt, in inflammatory bowel disease, 467
- Activated partial thromboplastin time, in antiphospholipid antibody syndrome, 405, 410-413
- Activated partial thromboplastin time inhibitor screen, in antiphospholipid antibody syndrome, 405
- Agarose gel tests, in antiphospholipid antibody syndrome, 409
- Alpha-1 antitrypsin, in inflammatory bowel disease, 467-468
- ANCAs (antineutrophil cytoplasmic antibodies), in inflammatory bowel disease, 469-474
- Angry, in tolerance, 334-335
- Angioedema, autoimmune aspects of, 563-566
hereditary, 565-566
in C1 inhibitor deficiency, 563-565
- Anticardiolipin antibodies, assays for, 409-410
clinical features of, 400-401
drug-induced, 399
types of, 413
- Anticoagulants, lupus. *See Lupus anticoagulant.*
therapeutic, in antiphospholipid antibody syndrome, 419-420
- Antigliadin antibody test. *See Gliadin antibody test.*
- Antihistone antibodies. *See Histone, antibodies to.*
- Anti-liver-kidney microsomal antibodies, in autoimmune hepatitis, 492-493
in primary biliary cirrhosis, 487
- Antimitochondrial antibodies, in interstitial cystitis, 574
in primary biliary cirrhosis, 486-489
mimickers of, 487
naturally occurring, 489
- Antineuronal antibody testing, in neuropsychiatric SLE, 385-386
- Antineutrophil cytoplasmic antibodies, in inflammatory bowel disease, 469-474
- Antinuclear antibodies, in autoimmune hepatitis, 491-492
in interstitial cystitis, 573-575
testing for, enzyme immunoassays for, 355-365
with silicone implant, 343-344, 346-347
screening, 348-349
- Antinucleolar antibodies, in interstitial cystitis, 573-575
- Antioxidants, in atherosclerosis protection, 597
- Anti-parietal cell antibody, in primary biliary cirrhosis, 487
- Antiphospholipid antibody(ies), 395-430
historical perspective of, 395-396
testing for, in neuropsychiatric SLE, 388
- Antiphospholipid antibody syndrome, clinical features of, 398-404
definition of, 398-399
epidemiology of, 398-399
familial, 399-400
immunology of, 396-398
laboratory studies in, 404-410
anticardiolipin antibodies in, 409-410
false-positive syphilis test, 410
indications for, 417-419
lupus anticoagulant in, 404-409
quality assurance in, 410-416
recommendations for, 416-417
therapy monitoring, 420-421
pathophysiology of, 396-398
primary, 399
secondary, 399
treatment of, 419-420
- Antiribosomal antibodies, versus antimitochondrial antibodies, 487
- Antiribosomal P protein antibodies, testing for, in neuropsychiatric SLE, 386-388
- Antismooth muscle antibodies, in autoimmune hepatitis, 492

- Antismooth muscle antibodies (*Continued*)
 in primary biliary cirrhosis, 487
- Antithyroid antibodies, in urticaria, 560-561
- Antitrypsin, in inflammatory bowel disease, 467-468
- Apoptosis, failure of, in Sjögren's syndrome, 439
- Arthritis, rheumatoid. See *Rheumatoid arthritis*.
- Aspirin, therapeutic, in antiphospholipid antibody syndrome, 419-420
- Atherosclerosis, oxidized low-density lipoprotein in. See *Low-density lipoprotein, oxidized*.
- Autoimmune disease, angioedema, 559-569
 antihistone antibodies in, 367-378
 antinuclear antibodies in. See *Antinuclear antibodies*.
 antiphospholipid antibodies in, 395-430
 atherosclerosis, 595-604
 celiac disease, 445-464
 concepts in, 329-353
 cytokines in, 547-558
 diabetes mellitus, 499-545
 experimental models of, 336-338
 hepatitis, 489-493
 hypoglycemia, 519
 inflammatory bowel disease, 465-481
 inner ear, 581-594
 interstitial cystitis, 571-579
 liver, 483-497
 pathophysiology of, 336-338
 primary biliary cirrhosis, 484-489
 primary sclerosing cholangitis, 473, 493-494
 silicone implants and, 341-353, 437-438
 Sjögren's syndrome, 431-444
 systemic lupus erythematosus. See *Systemic lupus erythematosus*.
 T-cell subset polarization in, 335-336
 tolerance and, 330-335
 urticaria, 559-569
- Autonomic neuropathy, in diabetes mellitus, 502
- B cells, selection of, for tolerance, 333-334
- Behçet's disease, inner ear dysfunction in, 586
- Beta cell destruction. See *Diabetes mellitus, insulin-dependent*.
- Biliary cirrhosis, primary, 484-489
- Biopsy, intestinal, in celiac disease, 457
 salivary gland, in Sjögren syndrome, 432-435, 438-439
- Bio-Rad enzyme immunoassay, for antinuclear antibodies, 362-364
- Bladder, interstitial cystitis of. See *Interstitial cystitis*.
- Brain cross-reactive lymphocytotoxic antibodies, testing for, in neuropsychiatric SLE, 387
- Breast implants, silicone. See *Silicone implants*.
- C1 inhibitor deficiency, autoimmune aspects of, angioedema in, 563-565
- Capture enzyme-linked immunosorbent assay, in glutamic decarboxylase antibody detection, 523-524
- Celiac disease, 445-464
 antigliadin antibodies in, 448-449
 biopsy in, 457
 clinical features of, 445
 connective tissue antibodies in, 449-451
 epidemiology of, 445
 genetic factors in, 446
 gluten challenge test in, 457-458
 humoral response in, 448-451
 intestinal secretion antibodies in, 457-458
 pathophysiology of, 446-448
 serodiagnosis of, 451-459
 clinical utility of, 453
 immunologic markers in, 451-453
 in dermatitis herpetiformis, 455-457
 in triage, 454-455
 screening, 453-455
 standardization of, 458-459
 versus biopsy, 457
 with gluten challenge test, 457-458
- Cell-mediated immunity, inflammatory bowel disease and, 474-475
- Cerebrospinal fluid analysis, in neuropsychiatric SLE, 386
- Chemokines, in inflammation mediation, 551
- Cholangitis, autoimmune, 489
 primary sclerosing, 493-494
 inflammatory bowel disease and, 473
- Cholestasis, in primary biliary cirrhosis, 485
- Cholesterol, oxidized low-density lipoprotein and. See *Low-density lipoprotein, oxidized*.
- Chromatin, antibodies to. See also *Histone, antibodies to*.
 structure of, 368
- Chronic fatigue syndrome, silicone implants and, 344-345
 Sjögren syndrome and, 435-437
- Coagulation disorders, in antiphospholipid antibody syndrome, 398-404
- Cogan's syndrome, inner ear dysfunction in, 586

- Colitis, ulcerative. See *Inflammatory bowel disease*.
- Collagen I, antibodies to, with silicone implant, 344
- Complement deposition, in inflammatory bowel disease, 467
- Connective tissue, antibodies to, in celiac disease, 449-451
- Connective tissue disease, silicone implants and, 345, 347-348
- Coxsackievirus infection, as insulin-dependent diabetes mellitus trigger, 508-509
- Crohn's disease. See *Inflammatory bowel disease*.
- Crypt abscess, in inflammatory bowel disease, 467
- Cyclophosphamide, in autoimmune inner ear disease, 584
- Cystitis, interstitial, autoantibodies in, 571-579
- Cytokines, 547-558
 - in autoimmune disease, 554-556
 - in Sjögren's syndrome, 439
 - in systemic lupus erythematosus, 385
 - mediating function of, 547-554
 - immunity, 551-552
 - inflammation, 549-551
 - lymphocyte activation and differentiation, 552-554
- Cytoplasmic antigens, antibodies to, in inflammatory bowel disease, 469-474
 - in interstitial cystitis, 573
 - islet cell, in insulin-dependent diabetes mellitus, 511-517, 528-530
- Deafness, sensorineural, rapidly progressive. See *Inner ear, autoimmune disease of*.
- Depletion enzyme-linked immunosorbent assay, in glutamic decarboxylase antibody detection, 523-524
- Dermatitis herpetiformis, serodiagnosis of, 455-457
- Diabetes mellitus, insulin-dependent, 499-545
 - antibodies in, alpha-cell, 516-517
 - environmental triggers of, 507-509
 - glutamic decarboxylase, 512, 520-525, 528-530
 - IA-2, 512, 525-530
 - insulin, 512, 517-520, 528-530
 - islet cell cytoplasmic, 511-517, 528-530
 - islet cell surface, 517
 - screening tests for, 528-533
 - types of, 511-513
 - beta-cell mass decline in, 509-510
 - clinical features of, 510
 - epidemiology of, 499-500
 - ethnic factors in, 516
 - fetal effects of, 502
 - genetic factors in, 503-506
 - glucose intolerance in, 510
 - management of, 503
 - natural history of, after diagnosis, 499-503
 - before diagnosis, 503-510
 - neuropathy in, 502
 - prediabetes recognition in, 510-527
 - prevention of, 527-533
 - remission of, 511
 - vascular disease in, 500-501
- Drugs, antiphospholipid antibody syndrome from, 399
 - lupus induction from, histone antibody testing in, 367-378
- Dryness, of eyes and mouth. See *Sjögren's syndrome*.
- dTTI (tissue thromboplastin inhibition) assay, in antiphospholipid antibody syndrome, 408, 413
- DVVtest (Russell viper venom) time test, in antiphospholipid antibody syndrome, 406-407, 410, 413-414
- Ear, inner, autoimmune disease of. See *Inner ear, autoimmune disease of*.
- Ecarin time test, in antiphospholipid antibody syndrome, 407
- Electroencephalography, in neuropsychiatric SLE, 388-389
- Elias enzyme immunoassay, for antinuclear antibodies, 362-364
- ELISAs. See *Enzyme-linked immunosorbent assays*.
- Embolism, in antiphospholipid antibody syndrome, 398-403
- Endomysial antibody test, in celiac disease, 449-451
 - clinical utility of, 453
 - in triage, 454-455
 - with gluten challenge test, 457-458
 - in dermatitis herpetiformis, 455-457
- Enteropathy, gluten-sensitive. See *Celiac disease*.
- Environmental agents, in insulin-dependent diabetes mellitus, 507-509
 - in Sjögren's syndrome, 440
- Enzymatic immunoprecipitation, in glutamic decarboxylase antibody detection, 523
- Enzyme immunoassays, for antinuclear antibodies, 355-365
 - comparison of, 357-364

612 INDEX

- Systemic lupus erythematosus, C1
 inhibitor deficiency in, 565
 neuropsychiatric, 380-381
 histone antibody testing in, 367-378
 inner ear dysfunction in, 585
 neuropsychiatric, 379-393
 antineuronal antibody testing in, 385-386
 antiphospholipid antibody testing in, 388
 antiribosomal P protein antibody testing in, 386-388
 brain cross-reactive lymphocytotoxic antibody testing in, 386
 cerebrospinal fluid analysis in, 385
 classification of, 380-381
 clinical features of, 381-382
 description of, 379-380
 diagnosis of, 384-390
 electroencephalography in, 388-389
 imaging in, 388-389
 immunopathogenesis of, 382-384
 pathology of, 382
 prospective diagnostic clinical study on, 389-390
 silicone implants and, 347
- T cells, activated, in SLE, 384
 autoimmune, in Sjögren's syndrome, 438-439
 dysfunction of, in inflammatory bowel disease, 474-475
 subsets of, polarization of, in autoimmune disease, 335-336
 tolerant, circumvention of, 333-334
 immune state of, 334-335
 selection of, 330-333
- Textarin time test, in antiphospholipid antibody syndrome, 407
- Thrombocytopenia, in antiphospholipid antibody syndrome, 403
- Thromboembolism, in antiphospholipid antibody syndrome, 398-403
- Thyroid, antibodies to, in urticaria, 560-561
- Tissue thromboplastin inhibition assay, in antiphospholipid antibody syndrome, 408, 413
- Tolerance, autoimmune disease and, 330-335
 circumvention of, 333-334
 experimental, 330-333
 immune state in, 334-335
 to self, 330
- Tolerization techniques, for insulin-dependent diabetes mellitus prevention, 528
- Transforming growth factor- β , in lymphocyte activation and differentiation, 553-554
- Tumor necrosis factor α , in autoimmune disease, 555
 in inflammation mediation, 549-550
- Ulcerative colitis. See *Inflammatory bowel disease*.
- Urticaria, autoimmune aspects of, 559-569
 antithyroid antibodies, 560-561
 immunoglobulin E and receptor antibodies, 561-562
 in vasculitis, 562
 mast cell degranulation in, 560-562
- Vascular disease, in diabetes mellitus, 500-501
- Vasculitis, in SLE, 384
 inner ear dysfunction in, 585-586
 leukocytic, in urticaria, 562
- Veneral Disease Research Laboratory (VDRL) test, false-positive, in antiphospholipid antibody syndrome, 410
- Ventriculoperitoneal shunt, silicone antibodies from, 349-350
- Vestibular dysfunction, in autoimmune inner ear disease, 584
- Viral infections, in Sjögren's syndrome, 440
- Warfarin, therapeutic, in antiphospholipid antibody syndrome, 419-420
- Wegener's granulomatosis, antineutrophil cytoplasmic antibodies in, 469
 inner ear dysfunction in, 586
- Western blot test, for histone antibodies, 372
 in interstitial cystitis, 573-575
- Zeus enzyme immunoassay, for antinuclear antibodies, 358-364